# EDGAR Filing Document

**Accession Number:** 0001141788
**File Stem:** 0001683168-25-006920
**Filing Date:** 2025-9
**Character Count:** 11816
**Document Hash:** e79b2e2f3f210b3a9161e63e6783f39b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-006920.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001683168-25-006920

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250912

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20250912

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HEALTH DISCOVERY CORP
- **CENTRAL INDEX KEY:** 0001141788
- **STANDARD INDUSTRIAL CLASSIFICATION:** PATENT OWNERS & LESSORS [6794]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 743002154
- **STATE OF INCORPORATION:** GA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-62216
- **FILM NUMBER:** 251312047

**BUSINESS ADDRESS:**
- **STREET 1:** 2002 SUMMIT BLVD NE, SUITE 300
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30319
- **BUSINESS PHONE:** (404) 566-4865

**MAIL ADDRESS:**
- **STREET 1:** 2002 SUMMIT BLVD NE, SUITE 300
- **CITY:** ATLANTA
- **STATE:** GA
- **ZIP:** 30319

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DIRECT WIRELESS COMMUNICATIONS INC
- **DATE OF NAME CHANGE:** 20010531

?xml version='1.0' encoding='ASCII'? HEALTH DISCOVERY CORPORATION Form 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): <u>**September 12, 2025**</u>

**<u>HEALTH DISCOVERY CORPORATION</u>**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **<u>GA</u>** | **<u>333-62216</u>** | **<u>74-3002154</u>** |
| (State of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **2002 SUMMIT BLVD, SUITE 300** |  |
| **<u>ATLANTA, GA</u>** | **<u>30319</u>** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(404) 566-4865</u>**

(Registrant's telephone number, including area code)

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:**

☐ Written communications pursuant to Rule 425 under the Securities Act.

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

Securities registered pursuant to Section 12(g) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, no par value | HDVY | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure**

On September 12, 2025, Health Discovery Corporation issued a letter to its shareholders providing an update to the Company's recent activity, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01 by reference.

 

*In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.* 

 

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp; [Letter to Shareholders](health_ex9901.htm)

104&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **HEALTH DISCOVERY CORPORATION** | **HEALTH DISCOVERY CORPORATION** |
|  | Registrant | Registrant |
| Dated: September 12, 2025 | By: | /s/ Alan K. Hauser |
|  |  | Alan K. Hauser<br> Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

September 12, 2025

Dear Fellow Shareholders,

I am writing to provide a straightforward update on what Health Discovery Corporation ("HDC", or the "Company") has been working on and how we are positioning the Company moving forward.

In the near-term, our top priorities are protecting the value of our intellectual property ("IP") and restoring our reporting with the Securities Exchange Commission ("SEC") so our shares can again trade on a recognized U.S. over-the-counter (OTC) marketplace.

*Intellectual Property Protection*

Over the past year, we believe that we have identified potential infringement of certain HDC intellectual property, including U.S. Patent No. 10,402,685 (the "'685 Patent"). While this patent expired in June of 2025, an infringing party may be liable for damages for a six-year lookback period. Guided by outside counsel, we are pursuing protection and enforcement to the fullest, which may include formal notices, licensing discussions, and, if warranted, litigation. To avoid prejudicing any potential lawsuit, we are keeping the identity of the counterparty and our legal strategy confidential at this time; however, we are preserving evidence, continuing technical claim analyses, and evaluating remedies and venues consistent with counsel's advice.

While we believe our claims have merit, we cannot guarantee success in any enforcement action. Outcomes of controversies of this nature are inherently uncertain and depend on a variety of factors, including facts, law, venue, timing, counterclaims and resources.

*Financials, Audit & Reporting Readiness*

With the objective of becoming current in our reporting with the SEC, we have engaged a bookkeeping provider and an independent registered public accounting firm to help bring our financials current and align our reporting with requirements under federal securities laws.

Once this effort is completed, we plan to once again list our shares for trading on a recognized U.S. OTC marketplace. This would entail identifying an exchange for which we are eligible (as the historic OTC Bulletin Board on which we previously traded was discontinued), submitting an application and undergoing a review and approval process. We cannot guarantee that HDC will be listed on an OTC marketplace in the future.

*Leadership & Governance*

 

Our Board of Directors believes that it is in the best interest of HDC and our shareholders to maintain continuity in leadership as we strive to accomplish the objectives discussed above. Accordingly, the Board has approved an extension of the Chief Executive Officer's employment agreement, subject to definitive documentation. The employment agreement will not guarantee continued service and will include, among other terms, customary termination provisions.

*Key Risk Factors*

 

Below is a discussion of material risk factors, which is limited to the matters discussed in this letter. This should not be construed as an exhaustive list of risks that may affect our business. The following issues, uncertainty and risks, among others, should be taken into account in evaluating our business and outlook.

&nbsp;&nbsp;&nbsp;&nbsp;· *Limited Disclosures*: HDC is not current
on its SEC reporting obligations, and as a result, limited information about our business and financial condition is available to shareholders.

&nbsp;&nbsp;&nbsp;&nbsp;· *IP Protection:* Our efforts in pursing
IP infringement claims in relation to the '685 Patent may be unsuccessful. Regardless of outcome, IP litigation can be very costly
and may exceed our resources or any award, in the event of a favorable outcome. In addition, if we are unsuccessful in protecting the
'685 Patent, we may not be able to commercialize it (or the value of commercialization may be limited) in the future.

&nbsp;&nbsp;&nbsp;&nbsp;· *Financing and Liquidity:* We have limited
cash on hand, and additional capital may be required to fund operations, audits, SEC reporting requirements and IP enforcement actions.
Required capital may not be available on acceptable terms.

&nbsp;&nbsp;&nbsp;&nbsp;· *OTC Trading:* An application by HDC to an OTC market may not
be accepted. Even if we are listed, our securities could be thinly traded and volatile. In addition, our ability to apply for listing
on an OTC market is dependent on the satisfactory completion of audited financial statements, requisite disclosures, establishment of
internal controls and other compliance matters; all of which could prevent or delay our listing.

&nbsp;&nbsp;&nbsp;&nbsp;· *Operational Limitations:* We are a small company that is dependent
on a limited team and third-party providers. Changes or transitions in personnel or third-party providers could adversely impact timelines
and outcomes.

&nbsp;&nbsp;&nbsp;&nbsp;· *External Factors:* Our future results may be affected by a number
of external factors over which we have little or no control, including, without limitation, macroeconomic, legal, regulatory and market
factors.

*Forward-Looking Statements*

 

Please be advised that this letter contains forward-looking statements. Forward-looking statements are projections of events, revenues, income, future economic performance or management's plans and objectives for our future operations. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks (including those discussed herein and in our public filings), uncertainties and other factors, any of which may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made, and we undertake no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Our team at HDC is focused on doing the hard, necessary work to accomplish these objectives. We will communicate material developments through appropriate channels as they become available. We thank you for your continued support.

Sincerely,<br>

![](image_001.jpg)

Alan K. Hauser<br> *Chief Executive Officer*

*Health Discovery Corporation*